In this study, we sought to determine whether using clinically available drugs targeting both histone deacetylase (HDAC) and PI3K/AKT activities can exploit these vulnerabilities in treatment-resistant AR-positive CRPC and AR-negative NEPC tumor phenotypes. The gene discussed is AKT1; the disease is neoplasm.